key: cord-0892376-j3zd69dh
authors: Kami, Wakaki; Kinjo, Takeshi; Arakaki, Wakako; Oki, Hiroya; Motooka, Daisuke; Nakamura, Shota; Fujita, Jiro
title: Rapid and simultaneous identification of three mutations by the Novaplex(TM) SARS-CoV-2 Variants I Assay kit
date: 2021-05-29
journal: J Clin Virol
DOI: 10.1016/j.jcv.2021.104877
sha: d40f8b5e1ac042f7e5ed91f5e0f4c48a58e461f5
doc_id: 892376
cord_uid: j3zd69dh

Background: The emergence of SARS-CoV-2 variants has caused an unexpected rebound globally. The World Health Organization has listed three variants (B.1.1.7, B.1.351, and P.1) as variants of concern. To understand the epidemiology and thereby plan appropriate safety measures, differential identification of the variants is indeed critical. Objectives: Although whole-genome sequencing is the gold standard for variant identification, it is time-consuming and relatively expensive. Therefore, a rapid, easy, and cost-effective platform targeting multiple regions of the genome is required. Here, we assessed the usefulness of the Novaplex(TM) SARS-CoV-2 Variants I Assay kit in identifying mutations in the variants. Study design: We retrospectively examined 30 stored nasal swabs from COVID-19-positive patients tested between November 2020 and March 2021. RNA extracted from these swabs was subjected to the commercial kit and real-time reverse transcription-PCR was performed. To determine the genome sequences of SARS-CoV-2 in the collected samples and deduce the consensus sequences among the identified variants, genome sequencing libraries were prepared and mapped to the reference genome. Results: Four of the tested samples were determined as variants. Of them, two harbored both H69/V70 deletion and N501Y substitution, whereas two harbored E484K substitution alone. Conclusions: The variant with E484K substitution alone (“R.1”) has been now categorized as a variant of interest in Japan. Additionally, the kit-based assay was found to be feasible, convenient, and user-friendly in identifying the abovementioned mutations with a turnaround time of only 2 hours.

Results: Four of the tested samples were determined as variants. Of them, two 51 harbored both H69/V70 deletion and N501Y substitution, whereas two harbored 52 E484K substitution alone. where they were first identified [2] . Among the various mutations emerging in Here, we report the utility of this commercial kit and discuss its implications in the 95 differential identification of SARS-CoV-2 variants. in the variants. We detected two samples with the E484K mutation and without 166 the N501Y mutation in this study. This variant has been named R.1 and 167 categorized as a VOI in Japan as of April 7, 2021; however, this variant could 168 bypass the screening stage in our country. Therefore, we need a 169 multiplex-based test that can examine several mutations simultaneously.

In conclusion, the Novaplex TM SARS-CoV-2 Variants I Assay is a simple, 171 rapid, and easy to perform method, and can identify three important mutations 172 simultaneously. An additional advantage of this commercial kit is that it can be 173 used with conventional real-time thermal cyclers. We believe that the 

World Health Organization, COVID-19 weekly epidemiological update

Proposed working definitions of SARS-CoV-2 variants of interest 191 and variants of concern

World Health Organization, Weekly epidemiological update on 196 COVID-19

Molecular dynamics simulation reveals E484K mutation enhances 205 spike RBD-ACE2 affinity and the combination of E484K K417n and N501y 206 mutations (501Y.V2 variant) induces conformational change greater than N501Y 207 mutant alone, potentially resulting in an escape mutant

Organization Reginal Office for Europe, Methods for the detection and 211 identification of SARS-CoV-2 variants

World Health Organization, Genomic sequencing of SARS-CoV-2: A 215 guide to implementation for maximum impact on public health

Development of genetic diagnostic methods for detection for novel coronavirus 219 2019 (nCoV-2019) in Japan

Disentangling primer interactions improves SARS-CoV-2 genome sequencing 223 by multiplex tiling PCR

Clinical utility of SARS-CoV-2 whole genome sequencing in deciphering

The authors have no conflicts to declare.

Acknowledgements 181 We would like to thank Editage (www.editage.com) for English language editing. 182 We also thank Dr. Kentaro Tanaka for his technical support in performing 183 genome analysis.